公开(公告)号：US20210346513A1

公开(公告)日：2021-11-11

申请号：US16636325

申请日：2018-08-03

Applicant: AMGEN INC.

Inventor： Michal ACHMATOWICZ ,  Dante ROMANINI ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Oliver R. THIEL

IPC: A61K47/68 ,  C07K16/28 ,  C07K14/605

Abstract: The present disclosure relates to a method of capping, reducing, and oxidizing cys-mAbs in order to provide homogenous material for subsequent conjugation reactions. The present method demonstrates robust ways to manufacture conjugates of cysteine-engineered antibodies that offer high yield and consistent product quality.

公开(公告)号：US20180311372A1

公开(公告)日：2018-11-01

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  C07K16/28 ,  A61P3/10

CPC classification number: C07K16/28 ,  A61K39/395 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20160024159A1

公开(公告)日：2016-01-28

申请号：US14773756

申请日：2014-03-12

Applicant: AMGEN INC

Inventor： Justin K. MURRAY ,  Jerry Ryan HOLDER ,  Malgorzata WANSKA ,  Christopher M. TEGLEY ,  James R. FALSEY ,  Elizabeth M. DOHERTY ,  Leslie P. MIRANDA ,  Kaustav BISWAS ,  Bin WU ,  Kelvin SHAM ,  Jason C. LONG

IPC: C07K14/435 ,  A61K38/17 ,  A61K47/48

CPC classification number: C07K14/43518 ,  A61K38/00 ,  A61K38/16 ,  A61K38/1709 ,  A61K38/1767 ,  A61K47/643 ,  A61K47/6817 ,  C07K14/435 ,  C07K14/46 ,  C07K14/47

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周受限制的NaV1.7抑制剂。 在一些公开的实施方案中，分离的多肽是NaV1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。

公开(公告)号：US20250121056A1

公开(公告)日：2025-04-17

申请号：US18982197

申请日：2024-12-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle M. VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K39/395 ,  A61K47/68 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20210154318A1

公开(公告)日：2021-05-27

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIENT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20150023988A1

公开(公告)日：2015-01-22

申请号：US14207445

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： Justin K. MURRAY ,  Jerry Ryan HOLDER ,  Malgorzata WANSKA ,  Christopher M. TEGLEY ,  James R. FALSEY ,  Elizabeth M. DOHERTY ,  Leslie P. MIRANDA

IPC: A61K47/48 ,  C07K16/00 ,  A61K38/17 ,  C07K14/435

CPC classification number: A61K47/48438 ,  A61K38/00 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6817 ,  C07K14/43518 ,  C07K14/705 ,  C07K16/44

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周限制的Nav1.7抑制剂。 在一些公开的实施方案中，分离的多肽是Nav1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。